Estrigenix Therapeutics’ Scientific Advisor, Dr. Pauline Maki Ph.D., Receives Health Education Visionary Award

Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce that Dr. Pauline Maki Ph.D., a member of our Scientific Advisory Board, is receiving the Health Education Visionary Award from The Society for Women’s Health Research (SWHR) at their 2003 Annual Awards Gala held in Washington D.C.

SWHR is honoring Dr. Maki Ph.D. for her significant research contributions that are improving understanding of key issues in women’s health, particularly around cognition, mood and brain function during pregnancy and menopause. SWHR will also recognize Dr. Maki Ph.D. for her leadership role as the former chair of the SWHR Interdisciplinary Network of Alzheimer’s disease, during which time she led a team to investigate the accuracy and impact of Alzheimer’s diagnostic tests for women and men.

Dr. Maki, Professor of Psychiatry, Psychology, and Obstetrics & Gynecology at the University of Illinois-Chicago, leads a research program focused on women, cognition, mood and dementia as these relate to menopause. The research Dr. Maki Ph.D. is doing regarding this National Institutes of Health (NIH) funded program utilizes multiple methods, including clinical trials of hormonal and non-hormonal treatments for menopausal symptoms, cohort studies on the natural history of cognition and brain function across the menopausal transition and neuroimaging studies.

Estrigenix Therapeutics joins all those attending the SWHR 2003 Annual Awards Gala in congratulating Dr. Maki on this well deserved recognition.